HER2 and YAP co-expression amplifies an autocrine growth-factor program that confers growth-factor independence in HER2-positive breast cancer

HER2-targeted therapies have improved outcomes in HER2-positive breast cancer, yet ~ 20% of tumours recur within five years and the mechanisms underlying the aggressive, treatment-resistant subset are incompletely defined. The Hippo-pathway effector YAP is implicated in this subset; here we explored the mechanistic role of YAP in HER2-driven aggressive oncogenic features using cell lines as a model system. We examined YAP expression by immunohistochemistry in 76 HER2-positive primary breast tumours with clinical follow-up. To dissect mechanism, we generated MCF10A mammary epithelial cell lines stably overexpressing HER2 and/or YAP and shYAP lines in both the parental and the HER2 background, and characterised proliferation, migration and signalling in complete and in growth-factor-reduced media. Whole-transcriptome RNA-sequencing was performed across all eight engineered lines. Combination treatments with verteporfin, dasatinib, trastuzumab and lapatinib were tested in SKBR3 and ZR-75-1 cells; YAP-target growth-factor transcripts were measured by RT-qPCR. In the patient cohort, high YAP expression showed numerical trends toward aggressive features (residual disease after NACT, recurrence, shorter disease-free survival), though none reached statistical significance in this underpowered cohort. In MCF10A, HER2 + YAP co-expression produced a significant but modest cooperative effect on proliferation and migration under standard growth conditions. Under growth-factor-reduced conditions, the cooperation became markedly synergistic, consistent with acquisition of autocrine self-sufficiency. YAP knockdown in the HER2 background reversed the proliferation and migration phenotypes and sensitised cells to trastuzumab. RNA-sequencing identified 238 genes synergistically up-regulated by HER2 + YAP and reversed by YAP knockdown, heavily enriched for autocrine growth factors (AREG, IL6, FSTL1, CCN1, CCN2/CTGF), chemokines and extracellular matrix components. In SKBR3 and ZR-75-1 cells, combined verteporfin + trastuzumab produced greater growth inhibition than either agent alone with concomitant down-regulation of the same autocrine growth factors. We describe a co-regulated YAP–HER2 transcriptional output that amplifies an autocrine growth-factor loop, as a candidate mechanism for the aggressive subset of HER2-positive disease with high YAP expression. These data provide preclinical rationale for combined YAP and HER2 inhibition; they do not establish a validated co-targetable vulnerability. Validation in HER2-amplified and trastuzumab-resistant models, in vivo, and ultimately in patients stratified by YAP expression is required.

Authors

Institutions

Publication Details

Journal
BMC Cancer
Published
2026-11-21
DOI
https://doi.org/10.1186/s12885-026-17390-4
Primary Topic
Hippo pathway signaling and YAP/TAZ
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

HER2 and YAP co-expression amplifies an autocrine growth-factor program that confers growth-factor independence in HER2-positive breast cancer

Tuan Zea Tan, Chaitanyanand B. Koppiker, Aditi Sanjay Khatpe, Madhura Kulkarni et al.
BMC Cancer
Hippo pathway signaling and YAP/TAZ
article

HER2 and YAP co-expression amplifies an autocrine growth-factor program that confers growth-factor independence in HER2-positive breast cancer

Tuan Zea Tan, Chaitanyanand B. Koppiker, Aditi Sanjay Khatpe, Madhura Kulkarni, Sunitha Manjari Kasibhatla, Rutvi Shah, Anirudha K. Puntambekar, Neeraj Bharti, Lingadahalli Subrahmanya Shashidhara, V Gomathi, Shruti Bhardiya, Bhavesh Vasave, Khushi Salvi
article en

Abstract

HER2-targeted therapies have improved outcomes in HER2-positive breast cancer, yet ~ 20% of tumours recur within five years and the mechanisms underlying the aggressive, treatment-resistant subset are incompletely defined. The Hippo-pathway effector YAP is implicated in this subset; here we explored the mechanistic role of YAP in HER2-driven aggressive oncogenic features using cell lines as a model system. We examined YAP expression by immunohistochemistry in 76 HER2-positive primary breast tumours with clinical follow-up. To dissect mechanism, we generated MCF10A mammary epithelial cell lines stably overexpressing HER2 and/or YAP and shYAP lines in both the parental and the HER2 background, and characterised proliferation, migration and signalling in complete and in growth-factor-reduced media. Whole-transcriptome RNA-sequencing was performed across all eight engineered lines. Combination treatments with verteporfin, dasatinib, trastuzumab and lapatinib were tested in SKBR3 and ZR-75-1 cells; YAP-target growth-factor transcripts were measured by RT-qPCR. In the patient cohort, high YAP expression showed numerical trends toward aggressive features (residual disease after NACT, recurrence, shorter disease-free survival), though none reached statistical significance in this underpowered cohort. In MCF10A, HER2 + YAP co-expression produced a significant but modest cooperative effect on proliferation and migration under standard growth conditions. Under growth-factor-reduced conditions, the cooperation became markedly synergistic, consistent with acquisition of autocrine self-sufficiency. YAP knockdown in the HER2 background reversed the proliferation and migration phenotypes and sensitised cells to trastuzumab. RNA-sequencing identified 238 genes synergistically up-regulated by HER2 + YAP and reversed by YAP knockdown, heavily enriched for autocrine growth factors (AREG, IL6, FSTL1, CCN1, CCN2/CTGF), chemokines and extracellular matrix components. In SKBR3 and ZR-75-1 cells, combined verteporfin + trastuzumab produced greater growth inhibition than either agent alone with concomitant down-regulation of the same autocrine growth factors. We describe a co-regulated YAP–HER2 transcriptional output that amplifies an autocrine growth-factor loop, as a candidate mechanism for the aggressive subset of HER2-positive disease with high YAP expression. These data provide preclinical rationale for combined YAP and HER2 inhibition; they do not establish a validated co-targetable vulnerability. Validation in HER2-amplified and trastuzumab-resistant models, in vivo, and ultimately in patients stratified by YAP expression is required.

BMC Cancer
Indian Institute of Science Education and Research Kolkata (IN), Centre for Development of Advanced Computing (IN), Ashoka University (IN), Prashanti Cancer Care Mission (IN), Cancer Science Institute of Singapore (SG)
Princeton Center for Complex Materials, Department of Biotechnology, Ministry of Science and Technology, India
Good health and well-being
Hippo pathway signaling and YAP/TAZ
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon